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PCardiac Resynchronization Therapy
enefit of Combined Resynchronization
nd Defibrillator Therapy in Heart Failure
atients With and Without Ventricular Arrhythmias
laudia Ypenburg, MD, Lieselot van Erven, MD, PHD, Gabe B. Bleeker, MD, Jeroen J. Bax, MD, PHD,
arianne Bootsma, MD, PHD, Maurits C. Wijffels, MD, PHD, Ernst E. van der Wall, MD, PHD,
artin J. Schalij, MD, PHD
eiden, the Netherlands
OBJECTIVES We attempted to assess the efficacy of combined cardiac resynchronization therapy-
implantable cardioverter-defibrillator (CRT-ICD) in heart failure patients with and without
ventricular arrhythmias.
BACKGROUND Because CRT and ICDs both lower all-cause mortality in patients with advanced heart
failure, combination of both therapies in a single device is challenging.
METHODS A total of 191 consecutive patients with advanced heart failure, left ventricular ejection
fraction35%, and a QRS duration120 ms received CRT-ICD. Seventy-one patients had
a history of ventricular arrhythmias (secondary prevention); 120 patients did not have prior
ventricular arrhythmias (primary prevention). During follow-up, ICD therapy rate, clinical
improvement after 6 months, and mortality rate were evaluated.
RESULTS During follow-up (18  4 months), primary prevention patients experienced less appropriate
ICD therapies than secondary prevention patients (21% vs. 35%, p  0.05). Multivariate
analysis revealed, however, no predictors of ICD therapy. Furthermore, a similar, significant,
improvement in clinical parameters was observed at 6 months in both groups. Also, the
mortality rate in the primary prevention group was lower than in the secondary prevention
group (3% vs. 18%, p  0.05).
CONCLUSIONS As 21% of the primary prevention patients and 35% of the secondary prevention patients
experienced appropriate ICD therapy within 2 years after implant, and no predictors of ICD
therapy could be identified, implantation of a CRT-ICD device should be considered in all
patients eligible for CRT. (J Am Coll Cardiol 2006;48:464–70) © 2006 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.072College of Cardiology Foundation
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Pespite significant advances in the treatment of congestive
eart failure (HF), the 5-year mortality exceeds 50% (1,2).
lthough the cause of death is HF-related in most patients
ith advanced symptoms, a significant proportion will die
uddenly and unexpectedly due to ventricular arrhythmias.
Cardiac resynchronization therapy (CRT) in New York
eart Association (NYHA) functional class III and IV
atients, with a wide QRS complex and depressed left
entricular (LV) function, has a positive effect on functional
tatus, quality of life, and LV function as demonstrated by
arious randomized and non-randomized studies (3–7).
urthermore, the CARE-HF (Cardiac Resynchronization-
eart Failure) study reported a positive effect of CRT on
ll-cause mortality, as compared with optimal medical
reatment alone (8). However, CRT alone will have a
imited effect on the arrhythmic death rate.
Implantable cardioverter-defibrillators (ICD) provide a
ubstantial mortality benefit by preventing sudden cardiac
eath in patients with previous ventricular arrhythmias (9).
From the Department of Cardiology, Leiden University Medical Center, Leiden,
he Netherlands. This work was supported the Dutch Heart Foundation, grant
o:2002B109.s
Manuscript received December 22, 2005; revised manuscript received April 7,
006, accepted April 11, 2006.urthermore, the SCD-HeFT (Sudden Cardiac Death in
eart Failure) trial showed that low left ventricular ejection
raction (LVEF) patients without ventricular arrhythmias,
egardless of the underlying cause, benefit from an ICD on
op of optimal medical therapy (10).
However, whether a combined CRT-ICD device should
e implanted in all CRT candidates is still a matter of
ebate. The randomized COMPANION (Comparison of
edical Therapy, Pacing and Defibrillation in Heart Fail-
re) trial showed a trend for CRT only to decrease mortal-
ty, but reported a significant mortality effect in patients
reated with a CRT-ICD device (11).
The aim of this study was to evaluate the number of ICD
herapies in patients eligible for CRT with and without prior
entricular arrhythmias, who received a combined CRT-ICD
evice, and whether predictors of ventricular tachycardia (VT)/
entricular fibrillation (VF) could be determined. Secondary
nd points were response to CRT and mortality differences in
atients with and without prior ventricular arrhythmias.
ETHODS
atients. From January 2000 to April 2004, all 195 con-
ecutive patients eligible for CRT-ICD in our center were
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August 1, 2006:464–70 Efficacy of CRT-ICD Therapyncluded in this prospective analysis. Standard therapy
uidelines were applied to indicate ICD implantation
12,13). Eligibility for CRT was based on the following
riteria: 1) advanced HF (NYHA functional class III or IV);
) LVEF 35%; and 3) wide QRS complex (120 ms)
ith a left bundle branch pattern on the electrocardiogram.
Patients with ischemic as well as non-ischemic dilated
ardiomyopathy were included. The etiology was considered
schemic in the presence of an old myocardial infarction
nd/or significant coronary artery disease (50% stenosis in
of the major epicardial coronary arteries) on coronary
ngiography, whereas patients with normal coronary arteries
ere classified as non-ischemic. All patients underwent
oronary angiography before implant. Patients with atrial
brillation or previous implanted pacemakers were also
ncluded in this analysis.
The study protocol was as follows. Before implant pa-
ients were allocated to 1 of 2 groups according to the
ndication for ICD implantation: 1) CRT-ICD insertion
as considered a primary preventive intervention in patients
ithout life-threatening sustained ventricular arrhythmias.
atients with non-sustained VT on Holter monitoring or
yncope without inducible ventricular arrhythmias during
lectrophysiological testing were also included in this pri-
ary prevention group; 2) CRT-ICD implantation was
onsidered a secondary preventive intervention in sudden
ardiac arrest survivors or in patients with sustained hemo-
ynamic unstable VT, as well as in patients with syncope
nd inducible ventricular arrhythmia at electrophysiological
esting (secondary prevention group).
For this analysis, follow-up was obtained up to 2 years.
he ICD printouts were obtained every 3 months. Clinical
valuation was assessed at baseline and after 6 months, and
hereafter at regular intervals.
RT-ICD implantation. A coronary sinus venogram was
btained using a balloon catheter, followed by the insertion of
he LV pacing lead into 1 of the posterolateral veins through
n 8-F guiding catheter (Easytrak 4512-80, Guidant Corp.,
t. Paul, Minnesota; or Attain-SD 4189, Medtronic Inc.,
inneapolis, Minnesota). The right atrial and ventricular
eads were positioned conventionally. All leads were con-
Abbreviations and Acronyms
ATP  antitachycardia pacing
CI  confidence interval
CRT  cardiac resynchronization therapy
HF  heart failure
HR  hazard ratio
ICD  implantable cardioverter-defibrillator
LV  left ventricle/ventricular
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
VF  ventricular fibrillation
VT  ventricular tachycardiaected to a dual-chamber biventricular ICD (Contak CD or aenewal, Guidant Corporation; Insync-III or Marquis,
edtronic Inc).
Procedural success was accomplished when pulse gener-
tor and the 3 leads were positioned without complications
nd biventricular pacing could be installed.
CD evaluation. During follow-up, ICD printouts were
btained every 3 months. From these printouts, the inci-
ence and type of arrhythmias, as well as the incidence of
ppropriate and inappropriate shocks, was determined.
hocks or antitachycardia pacing (ATP) were classified as
ppropriate when they occurred in response to VT or VF
nd as inappropriate when triggered by sinus or supraven-
ricular tachycardia, T-wave oversensing, or electrode dys-
unction. Cutoff rate of the monitor or first therapy zone
as noted.
linical evaluation. All patients were evaluated at the
utpatient clinic at baseline and at 6 months after CRT-
CD implantation. Heart failure symptoms were classified
sing the NYHA score. Quality-of-life score was assessed
sing the Minnesota Living with HF questionnaire (14). To
scertain biventricular pacing, a surface electrocardiogram
as obtained at all visits. Exercise tolerance was evaluated
sing a 6-min walk test at all visits (15). Resting
-dimensional echocardiography was performed at baseline
nd 6 months follow-up to assess LVEF. From the apical 2-
nd 4-chamber images, LVEF was determined using the
iplane Simpson’s rule (16).
After 6 months, patients were classified as responders,
ased on an improvement in NYHA functional class by 1
nd/or an improvement by 25% in 6-min walking dis-
ance, or as non-responders based on lack of improvement.
Thereafter, follow-up at the outpatient clinic was sched-
led at regular intervals. Events were classified as cardiac
eath (e.g., arrhythmic death, sudden cardiac death, death
ttributable to congestive HF, or myocardial infarction),
on-cardiac death, and heart transplantation.
tatistical analysis. Continuous data are presented as
ean  SD; dichotomous data are presented as numbers
nd percentages. Differences in baseline characteristics and
-month follow-up between independent patient groups are
valuated using unpaired Student t (continuous variables)
nd chi-square tests as well as a Mann-Whitney test
NYHA functional classification). Yates correction was used
n tables with a total 100 or with any cell containing a
alue 10. Data within patient groups (to compare the
ffect of CRT) were compared by the use of paired Student
tests (continuous variables) and Wilcoxon signed-rank
ests (NYHA functional classification). Event and survival
urves were determined according to the Kaplan-Meier
ethod, with comparisons of cumulative event rates by the
og-rank test.
Univariable and multivariable Cox regression analyses
ere performed to determine a relation between potential
isk factors at baseline, and the incidence of ICD therapy in
rimary prevention patients, secondary prevention patients,
nd both (primary end point); and death from any cause
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Efficacy of CRT-ICD Therapy August 1, 2006:464–70uring long-term follow-up (secondary end point). We
onsidered the following variables: age, gender, etiology,
RS duration, LVEF, medication, previous infarction, and
omorbidity. Responding to CRT and the indication for
CD therapy were added in the analysis of incidence of ICD
herapy in all patients. All variables entered the multivari-
ble stage, irrespective of the results of the univariable
nalyses. Multivariable regression was then performed ac-
ording to the principle of backward deletion. All variables
ith a p value of 0.25 remained in the final model. We
eport only adjusted hazard ratios (HRs) with their corre-
ponding 95% confidence intervals (CIs).
For all tests, a p value of 0.05 was considered statisti-
ally significant.
ESULTS
atient characteristics. A total of 195 consecutive patients
ith advanced HF underwent CRT-ICD implantation.
he procedure was successful in all patients and, except for
ocket hematoma in 9 and a pneumothorax in 1, no
rocedure-related complications were observed. One patient
ied 1 day after a “rescue” procedure due to refractory
ardiogenic shock. Three patients were lost for follow-up
all primary prevention patients). Follow-up of the remain-
ng 191 CRT-ICD patients (age 64  11 years, 153 men)
Table 1) was 18 months (range 25 days to 2 years).
nderlying etiology was ischemic in 107 patients (56%) and
on-ischemic in 84 patients (44%); NYHA functional class
efore implant was 2.9  0.5, QRS duration was 163  30
s, and LVEF was 21  7%. According to the initial
ndication for ICD implantation, 120 patients (101 prophy-
actic, 14 patients with non-sustained VT on Holter mon-
toring without inducible VT, 5 patients with syncope
ithout observed or inducible VT) were allocated to the
rimary prevention group (group 1); the secondary preven-
ion group (group 2) contained 71 patients (11 patients with
nducible VT, 38 patients with spontaneous VT, and 22
ut-of-hospital cardiac arrest survivors).
Patients in the secondary prevention group were more
ikely to have an ischemic cardiomyopathy (70% vs. 48%,
 0.01) and a previous myocardial infarction (62% vs.
2%, p  0.01). Usage of amiodarone was significantly
igher in the patients with prior ventricular arrhythmias.
mong patients in the primary prevention group, amioda-
one was initiated for the suppression of atrial fibrillation
n  18, 15%), whereas among secondary prevention pa-
ients amiodarone (n  39, 55%) was used for atrial
rrhythmia suppression in 4, VT suppression in 27, and
oth in 8 patients.
ncidence and therapy of ventricular arrhythmias. Dur-
ng follow-up, the incidence of ventricular arrhythmias (as
onitored by the device) was 24% in the primary prevention
roup and 39% in the secondary prevention group (p 
.05) (Table 2). The first ventricular arrhythmia episode was
erminated by ATP and/or shocks in 50 patients (88%). centricular arrhythmias (10 beats) with a cycle length in
he monitor zone received no therapy (12%). After the first
pisode of ventricular arrhythmias, the parameter settings of
he ICD were adjusted.
As expected (despite a significantly higher usage of
ntiarrhythmic drugs), secondary prevention patients re-
able 1. Baseline Characteristics
Variables
Primary
Prevention
(n  120)
Secondary
Prevention
(n  71)
All
Patients
(n  191)
en 94 (78%) 59 (81%) 153 (79%)
ge (yrs) 64  10 66  11 64  11
ollow-up (months) 19  6 18  7 18  6
tiology
Ischemic 57 (48%) 50 (70%)* 107 (56%)
Non-ischemic 63 (52%) 21 (30%)* 84 (44%)
RS duration (ms) 163  30 164  29 163  30
hythm
Sinus rhythm 87 (73%) 50 (70%) 138 (72%)
Paroxysmal atrial fibrillation 27 (22%) 15 (21%) 42 (22%)
Permanent atrial fibrillation 6 (5%) 6 (8%) 12 (6%)
Pacemaker rhythm 12 (10%) 9 (13%) 21 (11%)
VEF (%) 22  7 20  7 21  7
YHA functional class 2.9  0.5 3.0  0.5 2.9  0.5
RT-ICD indication
Prophylactic 101 (84%) 0 (0%) 101 (53%)
Non-sustained VT 14 (12%) 0 (0%) 14 (7%)
Syncope 5 (4%) 0 (0%) 5 (3%)
Inducible VT 0 (0%) 11 (15%) 11 (6%)
Spontaneous VT 0 (0%) 38 (54%) 38 (20%)
Spontaneous VF 0 (0%) 22 (31%) 22 (12%)
ardiovascular history
Previous infarction 38 (32%) 44 (62%)* 82 (43%)
Previous PCI 17 (14%) 16 (23%) 33 (17%)
Previous CABG 28 (23%) 13 (18%)† 41 (21%)
Previous valve surgery 10 (8%) 8 (11%) 18 (9%)
Previous device 16 (13%) 29 (41%)* 45 (24%)
Pacemaker 10 (8%) 8 (11%) 18 (9%)
ICD 2 (2%) 21 (30%)* 23 (12%)
CRT 4 (3%) 0 (0%) 4 (2%)
omorbidity
Diabetes mellitus 24 (20%) 13 (18%) 37 (19%)
Stroke/TIA 8 (7%) 15 (21%)* 23 (12%)
Peripheral vascular disease 11 (9%) 7 (10%) 18 (9%)
COPD 18 (15%) 7 (10%) 25 (13%)
edication
Antithrombotic therapy 107 (89%) 59 (83%) 166 (87%)
ACE inhibitor/ATII blocker 103 (86%) 58 (82%) 161 (84%)
Diuretic 98 (82%) 61 (86%) 159 (83%)
Spironolactone 54 (45%) 32 (45%) 86 (45%)
Beta-blocker
(including sotalol)
72 (59%) 33 (46%) 105 (55%)
Statin 50 (42%) 33 (46%) 83 (43%)
Digoxin 30 (25%) 19 (27%) 49 (26%)
Amiodarone 18 (15%) 39 (55%)* 57 (30%)
p  0.01 compared with primary prevention group; †p  0.025 compared with
rimary prevention group.
ACE  angiotensin-converting enzyme; ATII  angiotensin II receptor; CABG 
oronary artery bypass graft; COPD  chronic obstructive pulmonary disease; CRT 
ardiac resynchronization therapy; ICD  implantable cardioverter-defibrillator; LVEF
left ventricular ejection fraction; NYHA  New York Heart Association; PCI 
ercutaneous coronary intervention; TIA  transient ischemic attack; VF  ventricular
brillation; VT  ventricular tachycardia.eived more appropriate ICD therapy (n  25, 35%, 95%
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August 1, 2006:464–70 Efficacy of CRT-ICD TherapyI 24 to 46%) than primary prevention patients (n  25,
1%, 95% CI 14 to 28%, p  0.05). The 1-year ICD
herapy rate in the primary prevention group (although
ower than the 27% event rate in the secondary prevention
roup, p  0.01) was 15% (Fig. 1).
Of interest, the time between implant and first appropri-
te ICD therapy was similar in both groups (group 1: 9 
months; group 2: 8  7 months, p  NS). Furthermore,
he cycle length of the first ventricular arrhythmia triggering
CD therapy was the same in both groups (324  107 ms),
nd the average cutoff rate of the VT detection zone was set
t 165  18 beats/min in both groups.
redictors of ICD therapy. No differences were observed in
aseline clinical parameters between patients who received
ppropriate ICD therapy and patients who did not receive
herapy. No predictors of ICD therapy could be identified by
ultivariate analysis (including etiology, gender, age, QRS
uration, LVEF, medication, previous infarction, and co-
orbidity) in primary prevention patients. In secondary
revention patients, however, age (65 years, HR 0.249,
Table 2. Cardiovascular Events
Variables
Deaths
Heart transplantation
Ventricular arrhythmia (VT/VF)
Appropriate ICD therapy
Inappropriate shock
Cycle length of first ventricular arrhythmia (ms)
Time to first appropriate ICD therapy (months)
Cutoff rate VT zone (beats/min)
*p  0.01 compared with primary prevention group.
Abbreviations as in Table 1.*igure 1. Appropriate implantable cardioverter-defibrillator (ICD) therapy
ate in primary and secondary prevention patients.5% CI 0.066 to 0.941, p  0.05) and amiodarone usage
HR 0.150, 95% CI 0.040 to 0.565, p  0.05) were
ssociated with a decreased risk of ICD therapy.
nappropriate therapy. Fourteen patients (7%) experi-
nced inappropriate shocks (5% primary prevention group,
1% secondary prevention group, p  NS). The trigger for
nappropriate therapy was atrial arrhythmia in 10 patients,
inus tachycardia in 2 patients, T-wave oversensing in 1
atient, and sensing of diaphragm potentials in 1 patient.
linical parameters. At baseline, no differences in NYHA
unctional class, LVEF, and QRS duration were observed
etween primary and secondary prevention patients. After
RT implantation, NYHA functional class improved 1
lass in 145 patients (76%) and quality-of-life score changed
rom 40  16 to 24  19 (p  0.01). In addition, the
xercise capacity improved, as reflected by an increase in
-min walking distance from 300  137 m to 403  144 m
p  0.01) after 6 months of CRT. There were no
ignificant differences in clinical outcome parameters be-
ween the 2 groups (Table 3).
Accordingly, primary and secondary prevention patients
esponded equally to CRT therapy (75% vs. 77%, p  NS).
However, patients with ATP/shocks had, in contrast
ith patients without ATP/shocks, a lower response rate to
RT (65% vs. 80%, p  0.025) (Table 4). Vice versa,
linical response to CRT resulted in a 69% lower risk of
able 3. Clinical Parameters in Primary and Secondary
revention Patients
Variables
Primary
Prevention
(n  120)
Secondary
Prevention
(n  71)
All
Patients
(n  191)
YHA functional class
Baseline 2.9  0.5 3.0  0.5 2.9  0.5
Follow-up 1.9  0.6* 2.0  0.6* 1.9  0.6*
uality of life, questionnaire
Baseline 40  16 39  17 40  16
Follow-up 24  21* 23  16* 24  19*
-min hall walk test (m)
Baseline 297  145 305  123 300  137
Follow-up 401  155* 407  123* 403  144*
esponder 90 (75%) 55 (77%) 145 (76%)
Primary
revention
(n  120)
Secondary
Prevention
(n  71)
All
Patients
(n  191)
4 (3%) 13 (18%)* 19 (9%)
1 (1%) 1 (1%) 2 (1%)
29 (24%) 28 (39%)* 57 (30%)
25 (21%) 25 (35%)* 50 (26%)
6 (5%) 8 (11%) 14 (7%)
313  69 335  13 324  107
9  6 8  7 9  7
164  18 167  19 165  18Pp  0.01 compared with baseline parameters.
NYHA  New York Heart Association.
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Efficacy of CRT-ICD Therapy August 1, 2006:464–70eceiving ICD therapy in both groups (HR 0.308, 95% CI
.099 to 0.962, p  0.05).
ong-term follow-up. Seventeen (9%, group 1: 4 [3%];
roup 2: 13 [18%]) patients died within the 2-year
ollow-up period. Most deaths were due to end-stage HF; 1
atient died after myocardial infarction. No arrhythmic
eaths were observed. Two patients underwent heart
ransplantation.
Despite identical baseline functional status, secondary
revention patients accounted for more deaths than primary
revention patients (18% vs. 3%, p  0.05) (Table 2). The
-year survival was 91% in the secondary prevention group
nd 99% in the primary prevention group with a 2-year
urvival of, respectively, 96% and 79% (Fig. 2).
Multivariate analysis revealed advanced age and amioda-
one usage as independent predictors of death. Previous
entricular arrhythmias, etiology, and response to CRT had,
able 4. Clinical Parameters in Patients With and Without
CD Therapy
Variables
Patients With
ICD Therapy
(n  50)
Patients Without
ICD Therapy
(n  141)
YHA functional class
Baseline 3.0  0.5 2.9  0.5
Follow-up 2.1  0.6* 1.9  0.6*
uality of life, questionnaire
Baseline 41  17 40  16
Follow-up 28  16* 23  20*
-min hall walk test (m)
Baseline 296  124 301  142
Follow-up 385  146* 409  143*
esponder 32 (65%) 113 (80%)†
p  0.01 compared with baseline parameters; †p  0.025 compared with patients
ith ICD therapy.
Abbreviations as in Table 1.dFigure 2. Survival curve for primary and secondary prevention patients.owever, no influence on the relative risk of death. Impor-
antly, ICD therapy was not correlated with lives saved (HR
.185, 95% CI 0.305 to 4.598, p  NS).
The cumulative cardiac event rate including appropriate
herapy (ATP/shock), death, and heart transplantation is
hown in Figure 3. The 2 curves (primary and secondary
revention patients) diverge immediately after implant and
ontinue their paths, resulting in a 1-year event rate of 17%
n patients without arrhythmias and of 34% in patients with
rrhythmias.
ISCUSSION
he main findings of this study were: 1) secondary preven-
ion patients experienced more appropriate ICD therapy;
owever, 21% of the primary prevention patients received
ppropriate ICD therapy; 2) no predictors of ICD therapy
n primary prevention patients could be identified; 3)
atients with and without previous ventricular arrhythmias
ad a similar clinical benefit from CRT, although long-term
ollow-up showed a higher mortality rate in secondary
revention patients; and 4) clinical responders to CRT
howed a lower number of ICD therapies compared with
on-responders.
CD therapy. Fifty patients (26%) experienced ventricular
rrhythmias resulting in appropriate ICD therapy (ATP
nd/or shock) within 2 years after implant. As expected, and
espite the higher use of amiodarone in the secondary
revention group, secondary prevention patients received
ignificantly more ICD therapy than primary prevention
atients (35% vs. 21%). However, the results obtained in the
rimary prevention group are in line with the results of the
ADIT II (Multicenter Automatic Defibrillator Implan-
ation) study (26% ICD therapy in ischemic cardiomyopa-
hy patients, LVEF 30%) (13,17). Also, the SCD-HeFT
tudy (LVEF 35%, ischemic and non-ischemic heart
igure 3. Cardiac event curve for primary and secondary prevention
atients.isease patients) reported an incidence of 21% ICD therapy,
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August 1, 2006:464–70 Efficacy of CRT-ICD Therapyhough the follow-up period was longer in the SCD-HeFT
tudy (10). In a retrospective review of 978 CRT-ICD
atients of the MIRACLE-ICD (Multicenter InSync Im-
lantable Cardioversion Defibrillation Randomized Clinical
valuation) trial, it was reported that 28% of the secondary
revention patients experienced an appropriate shock at 12
onths’ follow-up, compared with only 14% of the primary
revention patients (18). Reported incidences of appropriate
CD therapy for secondary prevention patients vary from
3% (2-year follow-up) to 82% (10-year follow-up) (19–
2). In our study, 35% of the secondary prevention patients
eceived ICD therapy within 2 years of follow-up. Further-
ore, in line with previous studies, time to first appropriate
herapy was similar for both primary and secondary preven-
ion patients (9  7 months) (20,23).
Wilkoff et al. (18) reported that the cycle length of
entricular arrhythmias in primary prevention patients is
horter than the cycle length of ventricular arrhythmias in
econdary prevention patients (303  54 ms vs. 366  71
s, p  0.0001). In part, this difference was explained by
he rate-lowering effect of amiodarone, used by 44% of the
econdary prevention patients and 23% of the primary
revention patients. In contrast, we found no differences in
rrhythmia cycle length between the 2 groups. Notably, our
tudy contained 22 survivors of VF, who tended to experi-
nce arrhythmias at a faster rate than patients initially
reated because of sustained VT.
In this study, 23 patients with an ICD (2 primary
revention patients and 21 secondary prevention patients)
eceived an upgrade to a CRT-ICD device. The potential
eneficial effect of CRT on ventricular arrhythmias in
atients with HF is incompletely understood. Some small
tudies reported a decrease of the number of ventricular
rrhythmias after CRT, possibly due to LV reverse remod-
lling (24–27); however, others reported the opposite
28,29). A recently published meta-analysis of large ran-
omized CRT trials found no statistically significant effect
f CRT on VT/VF occurrence compared with ICD therapy
nly (30). Due to the relatively small number of patients, we
ere not able to detect a positive effect on VT/VF occur-
ence of CRT in the group of patients upgraded from ICD
nly to CRT-ICD.
As ICD therapy is costly and only 21% of the primary
revention patients received appropriate therapy, we tried to
dentify predictors of VT/VF in this group. However, we
ould not identify predictors of VT/VF in primary preven-
ion patients eligible for CRT.
esponse to CRT. The baseline characteristics of both
roups were (with the exception of the higher number of
schemic heart disease patients in the secondary prevention
roup and higher amiodarone usage in this group) more or
ess identical. Furthermore, the efficacy of CRT, as reflected
y the improvement of functional status, was similar in both
roups, which is in line with the results of larger random-
zed trials (3,4,6,7,11). pAs reported by others, not all patients (46 patients, 24%)
esponded to CRT. This relatively high number reflected
he inability to predict a positive outcome by applying the
urrent inclusion criteria and warrants a further refinement
f these criteria (3,31,32). Of interest, response to CRT was
ssociated with a lower risk of receiving ICD therapy.
ortality. Two-year mortality was 9%. No arrhythmic
eaths were observed, and most deaths were HF related.
arge randomized HF trials in patients without ventricular
rrhythmias reported 2-year mortality rates between 12%
nd 30%, which is much higher compared with the 4
rimary prevention patients who died in this study (2-year
ortality rate 4%, Fig. 2) (8,10,11,13). Notably, sudden
ardiac death accounted for 35% of all deaths in the
ARE-HF study (8).
In contrast, the 18% mortality rate observed in secondary
revention patients was comparable to the mortality rate
eported by some secondary sudden cardiac death preven-
ion trials (9). Secondary prevention patients were more
ikely to have ischemic heart disease, more previous myo-
ardial infarctions, more ventricular arrhythmias, and a
igher amiodarone usage: in other words, comprise a sicker
atient group. As expected, advanced age (65 years) was
ssociated with a higher mortality rate. Furthermore, ami-
darone usage was also found to be an independent predic-
or of death. This is in line with a recent study by Kies et al.
33), who evaluated 300 sudden cardiac death survivors with
n ischemic cardiomyopathy. They also reported that ami-
darone was associated with a higher mortality.
tudy limitations. This was a non-randomized observa-
ional study performed to evaluate outcome differences
etween different ICD indication groups, which, actually,
eflect daily clinical practice. A control group would have
nderlined our results; however, all patients had an ejection
raction below 35% and therefore an indication for an ICD
nsertion, as well as an indication for CRT. The primary and
econdary prevention groups were not entirely comparable;
he secondary prevention group accounted for many more
schemic patients. However, etiology was not identified as
n independent predictor for ICD therapy or death.
Power calculation was not performed in this prospective
tudy, because the incidence of ICD therapy in patients
ith and without prior ventricular arrhythmias was un-
nown at the start of the study. The sample size of 191
atients may be too small to identify predictors of VT/VF,
nd explains its inability to predict them. Also, assumption
f the clinical efficacy of ICD therapies is needed, because
he number of ICD therapies does not correlate with the
umber of lives saved from SCD. Larger studies are needed
o further evaluate these issues.
onclusions. Despite a higher incidence of VT/VF epi-
odes in secondary prevention patients, 21% of the primary
revention patients did receive appropriate ICD therapy
uring follow-up, and no predictors could be identified
efore implant. Furthermore, CRT is effective in HF
atients with and without prior ventricular arrhythmias.
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TP or shocks.
These data suggest that a combined CRT-ICD device
hould be implanted in all patients eligible for CRT.
owever, the data also suggest that specificity of the
election criteria for ICD therapy is low, and efforts should
e made to increase the number of patients who will truly
enefit from combined CRT-ICD therapy.
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